Home›People›David Persing
David Persing

David Persing

Executive vice president and chief medical officer at Cepheid; director of Inflammatix

DirectorPublic company
Updated Nov 19, 2026·Latest SEC filing Nov 19, 2026·Suggest an edit

About David Persing

David Persing is executive vice president and chief medical officer at Cepheid, where he has worked since 2005. His work there has focused on diagnostic tests for infections and cancer.

He earned his MD and PhD degrees in 1988 and completed laboratory medicine residency training at Yale. In the early 1990s, he helped design and build Mayo Clinic's first PCR reference laboratory. From 2017 through 2023, Persing served as chief scientific officer for Danaher's Diagnostics platform after Danaher acquired Cepheid. He is a director of Inflammatix, which develops rapid tests that read immune responses to help physicians diagnose acute infections and sepsis.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name David Persing in the role, so the role may have started earlier or lasted longer.

Inflammatix, Inc. Current
EVP/Chief Medical Officer, Cepheid and director
2020 – Present · Sunnyvale, CA
Inflammatix helps emergency teams identify infection type and illness severity from the body's immune response.
Cepheid Current
EVP, Chief Med/Tech Officer and director
Executive Vice President and Chief Medical Officer (2005 – Present)
2005 – Present · Public company (CPHD)
Danaher Diagnostics
Chief Scientific Officer
2017 – 2023
Monogram Biosciences, Inc.
Director
2006 – 2009 · Public company (MGRM)

Key Colleagues at Startups

The people David Persing works with at each company, as listed on that company's latest Form D.

Inflammatix, Inc. · Form D, Nov 19, 2026
Timothy Sweeney
Timothy Sweeney
Co-Founder and CEO, director
FK
Florian Kainzinger
Founder, Think.Health Ventures and director
IC
Ingo Chakravarty
Operating Partner at Northpond Ventures and director
Steven Tablak
Steven Tablak
Former Chairman and CEO, GeneWeave
JR
Jonathan Romanowsky
Co-Founder and director

Sources

  1. SECInflammatix, Inc. Form D, filed Nov 19, 2026
  2. SECForms 3, 4 and 5 filed by David Persing (SEC filer 1263113)
  3. P2Inflammatix — Home